Vaso-occlusive Crisis clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Sorry, not currently recruiting here
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
Oakland, California and other locations
Our lead scientists for Vaso-occlusive Crisis research studies include Elliot Vichinsky, MD.
Last updated: